Search Results - "Fu, A.Z."

Factors Associated With Discontinuation of Sulfonylurea Therapy In Type 2 Diabetes Patients Who Initiate Insulin by Laires, P, Fu, A.Z, Iglay, K, Qiu, Y

Get full text

Underutilization Of Antihyperglycemic Dual Therapy In Eligible, Treatment-Naïve Patients With Type 2 Diabetes by Qiu, Y, Fu, A.Z, Davies, M.J, Engel, S.S

Get full text

Utilization Of Bevacizumab Among Medicare Patients With Colorectal Cancer Receiving Chemotherapy by Fu, A.Z, Tsai, H.T, Potosky, A.L

Get full text

PCV57 HEALTH CARE RESOURCE UTILIZATION AMONG T2DM PATIENTS WITH PRE-EXISTING MACROVASCULAR CONDITIONS: A MATCHED COHORT STUDY by Qiu, Y, Fu, A.Z

Get full text

PDB15 Initiation of Insulin Occurred More Frequently and Earlier in Older Patients with Type 2 Diabetes Treated With Initial Sulfonylurea Monotherapy Than With Metformin by Qiu, Y, Fu, A.Z, Davies, M.J, Engel, S.S

Get full text

PDB4 Characterization of the Risk for Urinary Tract Infections in US Patients with Type 2 Diabetes Mellitus by Lento, K, Qiu, Y, Fu, A.Z, Engel, S.S, Shankar, R, Davies, M.J, Brodovicz, K

Get full text

PCN104 HOSPITAL COSTS OF ADVERSE EVENTS IN PATIENTS RECEIVING TREATMENT FOR METASTATIC COLORECTAL CANCER by Fu, A.Z, Zhao, Z, Wang, S, Gao, S, Barber, B, Liu, G

Get full text

Using an automated recruitment process to generate an unbiased study sample of multiple sclerosis patients by Miller, Deborah M, Fox, R, Atreja, A, Moore, S, Lee, J-C, Fu, A Z, Jain, A, Saupe, W, Chakraborty, S, Stadtler, M, Rudick, R A

“…The objective of this study was to test the efficiency of an automated recruitment methodology developed as a component of a practical controlled trial to…”
Get more information

6059 Comorbidities in patients with metastatic colorectal cancer (mCRC) by Fu, A.Z, Zhao, Z, Wang, P.F, Barber, B, Liu, G.G

Get full text

PMH13 Healthcare Resource Utilization and Costs before and after Long-Acting Injectable Antipsychotic (LAI) Use in Commercially Insured Young Adults with Schizophrenia by Fu, A.Z., Pesa, J., Lakey, S., Benson, C.

Get full text

PMU28 Association between Social Determinants of Health and Depression Among Patients with Psoriasis in the US by Cai, Q, Pesa, J., Wang, R., Fu, A.Z.

Get full text

Current treatment landscape in triple negative breast cancer: A systematic literature review by Fu, A.Z., Kuang, Y., Fazeli, M.S., Kumar, N., Davis, C.

Get full text

PCN132 - Utilization Of Bevacizumab Among Medicare Patients With Colorectal Cancer Receiving Chemotherapy by Fu, A.Z., Tsai, H.T., Potosky, A.L.

Get full text

PDB120 - Factors Associated With Discontinuation of Sulfonylurea Therapy In Type 2 Diabetes Patients Who Initiate Insulin by Laires, P., Fu, A.Z., Iglay, K., Qiu, Y.

Get full text

Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study by Tsai, H.-T., Isaacs, C., Fu, A. Z., Warren, J. L., Freedman, A. N., Barac, A., Huang, C.-Y., Potosky, A. L.

“…Randomized controlled trials have reported a 4–5 times increased risk of heart failure (HF) in breast cancer patients receiving trastuzumab (Herceptin ® )…”
Get full text

PDB86 - Underutilization Of Antihyperglycemic Dual Therapy In Eligible, Treatment-Naïve Patients With Type 2 Diabetes by Qiu, Y., Fu, A.Z., Davies, M.J., Engel, S.S.

Get full text

Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study by Tsai, H.-T., Marshall, J.L., Weiss, S.R., Huang, C.-Y., Warren, J.L., Freedman, A.N., Fu, A.Z., Sansbury, L.B., Potosky, A.L.

“…Cardiovascular risk attributable to bevacizumab (Avastin®, BEV) for treatment of metastatic colorectal cancer (CRC) remains unclear. We conducted a…”
Get full text

Risk of cardiovascular adverse events from trastuzumab by Isaacs, C, Tsai, H.-T, Freedman, A.N, Barac, A, Huang, C.-Y, Potosky, A.L, Fu, A.Z, Warren, J.L

“…Randomized controlled trials have reported a 4-5 times increased risk of heart failure (HF) in breast cancer patients receiving trastuzumab (Herceptin[R])…”
Get full text

Efficacy of Growth Factors Compared to Chemotherapy in Low-Risk Myelodysplastic Syndromes by Golshayan, A., Fu, A.Z., Kattan, M.W., Brown, S., Maciejewski, J.P., Sekeres, M.A.

“…The myelodysplastic syndromes (MDS) represent a heterogeneous group of disorders with different underlying disease biologies and prognoses. Low-risk MDS,…”
Get full text

A longitudinal study on infant growth during the first sixth months of life, in relation to the nutrition of the lactating mothers and to the breastmilk output by Chen, X C, Liu, D S, Fu, A Z, Yan, H C, Yin, T A, Jing, Y S, Xu, Q M

Get more information